EA201200054A1 - Лечение токотриенолами или экстрактами, богатыми токотриенолами, первазивных расстройств развития - Google Patents
Лечение токотриенолами или экстрактами, богатыми токотриенолами, первазивных расстройств развитияInfo
- Publication number
- EA201200054A1 EA201200054A1 EA201200054A EA201200054A EA201200054A1 EA 201200054 A1 EA201200054 A1 EA 201200054A1 EA 201200054 A EA201200054 A EA 201200054A EA 201200054 A EA201200054 A EA 201200054A EA 201200054 A1 EA201200054 A1 EA 201200054A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- tokotrienols
- tocotrienol
- rich
- extracts
- treatment
- Prior art date
Links
- 239000000284 extract Substances 0.000 title abstract 2
- 208000023339 Pervasive Child Development disease Diseases 0.000 title 1
- 229930003802 tocotrienol Natural products 0.000 abstract 4
- 239000011731 tocotrienol Substances 0.000 abstract 4
- 235000019148 tocotrienols Nutrition 0.000 abstract 4
- 208000029560 autism spectrum disease Diseases 0.000 abstract 3
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 abstract 2
- 208000012202 Pervasive developmental disease Diseases 0.000 abstract 2
- 208000024825 childhood disintegrative disease Diseases 0.000 abstract 2
- -1 tocotrienol ester Chemical class 0.000 abstract 2
- 208000036640 Asperger disease Diseases 0.000 abstract 1
- 201000006062 Asperger syndrome Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000012239 Developmental disease Diseases 0.000 abstract 1
- 208000006289 Rett Syndrome Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26962709P | 2009-06-25 | 2009-06-25 | |
| PCT/US2010/025447 WO2010151348A1 (en) | 2009-06-25 | 2010-02-25 | Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201200054A1 true EA201200054A1 (ru) | 2012-05-30 |
Family
ID=43386829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201200054A EA201200054A1 (ru) | 2009-06-25 | 2010-02-25 | Лечение токотриенолами или экстрактами, богатыми токотриенолами, первазивных расстройств развития |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20120122969A1 (cg-RX-API-DMAC10.html) |
| EP (2) | EP2445519A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2012531411A (cg-RX-API-DMAC10.html) |
| BR (1) | BRPI1011776A2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2765771A1 (cg-RX-API-DMAC10.html) |
| EA (1) | EA201200054A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2011013558A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2010151348A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005033092A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
| EA035619B1 (ru) * | 2005-06-01 | 2020-07-16 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Композиции для использования в способе лечения митохондриальных нарушений |
| EP1986636B1 (en) | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| PL2220030T3 (pl) | 2007-11-06 | 2016-07-29 | Bioelectron Tech Corp | Pochodne 4-(p-chinonylo)-2-hydroksybutanamidu do leczenia chorób mitochondrialnych |
| EP2237664A4 (en) | 2008-01-08 | 2013-05-22 | Edison Pharmaceuticals Inc | (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES |
| WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| EP2303824B1 (en) * | 2008-06-25 | 2015-03-25 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| EP2344142B1 (en) | 2008-09-10 | 2024-06-26 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| CA2740773A1 (en) | 2008-10-14 | 2010-04-22 | Edison Pharmaceuticals, Inc. | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| WO2010051277A1 (en) | 2008-10-28 | 2010-05-06 | Edison Pharmaceuticals, Inc. | Process for the production of alpha-tocotrienol and derivatives |
| CA2777479C (en) | 2009-04-28 | 2017-10-17 | Ptc Therapeutics, Inc. | Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones |
| NO2470168T3 (cg-RX-API-DMAC10.html) * | 2009-08-26 | 2018-06-30 | ||
| CA2842486C (en) | 2011-07-19 | 2022-09-06 | Edison Pharmaceuticals, Inc. | Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
| KR20150082109A (ko) | 2012-11-13 | 2015-07-15 | 고다겐 파마슈티컬스 피티와이 엘티디 | 토코트리에놀의 경점막 전달 |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| CN105744835A (zh) * | 2013-07-22 | 2016-07-06 | 俄亥俄州国家创新基金会 | 用于减少热潮红发生的方法 |
| HUE058877T2 (hu) | 2014-12-16 | 2022-09-28 | Ptc Therapeutics Inc | (R)-2-hidroxi-2-metil-4-(2,4,5-trimetil-3,6-dioxociklohexa-1,4-dienil)butánamid polimorf és amorf alakjai |
| JP7117241B2 (ja) | 2015-12-16 | 2022-08-12 | ピーティーシー セラピューティクス， インコーポレイテッド | 混合されたトコール組成物からアルファ－トコトリエノールを富化するための改良された方法 |
| EP3389646A1 (en) | 2015-12-17 | 2018-10-24 | BioElectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| HUE066196T2 (hu) | 2018-10-17 | 2024-07-28 | Ptc Therapeutics Inc | 2,3,5-trimetil-6-nonilciklohexa-2,5-dién-1,4-dion alfa-szinukleinopátiák, tauopátiák és egyéb rendellenességek szuppresszálására és kezelésére |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| CA3136303A1 (en) * | 2019-04-05 | 2020-10-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Diagnostic for childhood risk of autism spectrum disorder |
| MY196888A (en) * | 2019-11-19 | 2023-05-08 | Hovid Berhad | A composition for managing cadasil |
| EP3981397A1 (en) * | 2020-10-08 | 2022-04-13 | Global Scientific | Tocotrienols derivates, methods and uses thereof |
| EP4366700A1 (en) | 2021-07-08 | 2024-05-15 | PTC Therapeutics, Inc. | Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0788376B2 (ja) | 1986-09-02 | 1995-09-27 | エーザイ株式会社 | 光学活性α−トコトリエノ−ルの製造方法 |
| JP2685785B2 (ja) | 1988-03-11 | 1997-12-03 | エーザイ株式会社 | 光学活性α−トコトリエノールの製造方法 |
| AU618791B2 (en) | 1988-03-16 | 1992-01-09 | Bioindustry Development Centre | Production of high concentration tocopherols and tocotrienols from palm oil by-product |
| US5157132A (en) | 1990-05-18 | 1992-10-20 | Carotech Associates | Integrated process for recovery of carotenoids and tocotrienols from oil |
| EP0543417A1 (en) | 1991-11-22 | 1993-05-26 | Lipogenics, Incorporated | Tocotrienols and tocotrienol-like compounds and methods for their use |
| US20030134028A1 (en) * | 1995-06-01 | 2003-07-17 | Lipton, Division Of Conopco, Inc. | Fat based food products |
| EP1051412B1 (en) | 1998-01-29 | 2003-09-24 | Eastman Chemical Company | Methods for separating a tocotrienol from a tocol-containing mixture and compositions thereof |
| US6472378B2 (en) | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
| US6187811B1 (en) * | 1998-10-28 | 2001-02-13 | Lipogenics, Inc. | Methods for treating benign prostatic hyperplasia using tocotrienols |
| US6562372B1 (en) | 1998-11-06 | 2003-05-13 | Fuji Chemical Industry Co., Ltd. | Tocotrienol-containing powder, a process for preparing it and a tablet comprising compressed said powder into a tablet form |
| US6761903B2 (en) * | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
| US6395915B1 (en) | 1999-09-10 | 2002-05-28 | Technikrom, Inc. | Method for producing purified tocotrienols and tocopherols using liquid chromatography |
| MY127451A (en) | 1999-11-04 | 2006-12-29 | Malaysian Palm Oil Board | A method of chromatographic isolation for vitamin e isomers |
| US20030206972A1 (en) * | 2000-10-13 | 2003-11-06 | Babish John G. | Compositions containing carotenoids and tocotrienols and having synergistic antioxidant effect |
| US20020155170A1 (en) * | 2000-11-30 | 2002-10-24 | Walsh William John | Nutrient supplements and methods for treating autism and for preventing the onset of autism |
| US6838104B2 (en) | 2000-12-20 | 2005-01-04 | Archer Daniels Midland Company | Process for the production of tocotrienols |
| US7217133B2 (en) * | 2002-04-04 | 2007-05-15 | Jeanine Thomas | Method for treating pervasive development disorder |
| AT414082B (de) * | 2002-05-03 | 2006-09-15 | Vis Vitalis Lizenz & Handels | Verfahren zur herstellung von tocotrienol-angereicherten präparationen |
| WO2005035491A2 (en) | 2003-10-10 | 2005-04-21 | Yasoo Health, Inc. | PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS FROM 2- VINYLCHROMANE COMPOUND |
| MXPA06009529A (es) | 2004-02-23 | 2007-04-10 | Texas A & M Univ Sys | Composiciones antioxidantes y metodos para el uso de las mismas. |
| ES2732293T3 (es) * | 2007-02-22 | 2019-11-21 | Childrens Hospital & Res Center At Oakland | Formulaciones de ácidos grasos y métodos para el uso de las mismas |
| KR101481197B1 (ko) | 2007-05-24 | 2015-01-09 | 로더스 크로클란 비.브이. | 토코페롤 및 토코트리에놀을 함유하는 조성물의 제조방법 |
-
2010
- 2010-02-25 JP JP2012517509A patent/JP2012531411A/ja active Pending
- 2010-02-25 MX MX2011013558A patent/MX2011013558A/es not_active Application Discontinuation
- 2010-02-25 EP EP10792467A patent/EP2445519A4/en not_active Withdrawn
- 2010-02-25 EA EA201200054A patent/EA201200054A1/ru unknown
- 2010-02-25 US US13/380,802 patent/US20120122969A1/en not_active Abandoned
- 2010-02-25 BR BRPI1011776A patent/BRPI1011776A2/pt not_active IP Right Cessation
- 2010-02-25 WO PCT/US2010/025447 patent/WO2010151348A1/en not_active Ceased
- 2010-02-25 CA CA2765771A patent/CA2765771A1/en not_active Abandoned
- 2010-02-25 EP EP13161401.8A patent/EP2609921A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012531411A (ja) | 2012-12-10 |
| EP2445519A1 (en) | 2012-05-02 |
| US20120122969A1 (en) | 2012-05-17 |
| CA2765771A1 (en) | 2010-12-29 |
| MX2011013558A (es) | 2012-04-30 |
| WO2010151348A1 (en) | 2010-12-29 |
| EP2445519A4 (en) | 2012-12-26 |
| BRPI1011776A2 (pt) | 2018-03-13 |
| EP2609921A1 (en) | 2013-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011013558A (es) | Tratamiento del trastorno pervasivo del desarrollo con tocotrienoles o extractos de tocotrienoles enriquecidos. | |
| EA201692166A1 (ru) | Гетероциклические ингибиторы глютаминазы | |
| BR112013013167A8 (pt) | inibidores de bromodomínio e usos dos mesmos | |
| MX363223B (es) | Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox. | |
| EA201391290A1 (ru) | Гетероциклические модуляторы синтеза липидов | |
| EA201170396A1 (ru) | 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции | |
| EA201291034A1 (ru) | АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ B-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ | |
| EA201500362A1 (ru) | Ингибиторы rho-киназы | |
| EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
| NZ702458A (en) | Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof | |
| EA201290919A1 (ru) | Индазольные соединения и их применение | |
| EA201790134A3 (ru) | Соединения имидазопирролидинонов | |
| EA201492005A1 (ru) | Бензамидные производные для ингибирования активности abl1, abl2 и bcr-abl1 | |
| WO2014062720A3 (en) | Methods of treating cancer | |
| ECSP14015609A (es) | Inhibidores de pde9 con estructura básica de imidazotriazinona | |
| EA201591616A1 (ru) | Трифторметил-замещенные аннелированные пиримидины и их применение | |
| EA202190619A1 (ru) | Противовирусные соединения | |
| EA201171286A1 (ru) | Новая технология изготовления индометацина | |
| EA033811B1 (ru) | Стабильные бесконсервантные мидриатические и противовоспалительные растворы для инъекций | |
| EA201490516A1 (ru) | Бифенилкарбоксиамиды в качестве ингибиторов rock-киназ | |
| EA201790032A1 (ru) | Бициклически замещённые урацилы и их применение | |
| EA201590667A1 (ru) | Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний | |
| NO20092019L (no) | Behandling av gjennomtrengende utviklingsforstyrrelser | |
| EA201491500A1 (ru) | Способы лечения фиброза | |
| EA201200570A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 |